



**HAL**  
open science

## **Factors associated with poor outcomes among adults hospitalised for influenza in France: A three-year prospective multicenter study**

Paul Loubet, Nezha Samih-Lenzi, Florence Galtier, Philippe Vanhems, Pierre Loulergue, Xavier Duval, Stéphane Jouneau, Déborah Postil, Sylvie Rogez, Martine Valette, et al.

### ► To cite this version:

Paul Loubet, Nezha Samih-Lenzi, Florence Galtier, Philippe Vanhems, Pierre Loulergue, et al.. Factors associated with poor outcomes among adults hospitalised for influenza in France: A three-year prospective multicenter study. *Journal of Clinical Virology*, 2016, 79, pp.68-73. 10.1016/j.jcv.2016.04.005 . hal-01302409

**HAL Id: hal-01302409**

**<https://univ-rennes.hal.science/hal-01302409>**

Submitted on 14 Apr 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Factors associated with poor outcomes among adults hospitalised for influenza in France: A three-year prospective multicenter study

Paul Loubet<sup>a,b,c</sup>, Nezha Samih-Lenzi<sup>d</sup>, Florence Galtier<sup>e</sup>, Philippe Vanhems<sup>f,g</sup>, Pierre Loulergue<sup>a,c,d</sup>, Xavier Duval<sup>h,i</sup>, Stéphane Jouneau<sup>j</sup>, Déborah Postil<sup>k</sup>, Sylvie Rogez<sup>l</sup>, Martine Valette<sup>m</sup>, Corinne Merle<sup>n</sup>, Corinne Régis<sup>o</sup>, Yolande Costa<sup>h</sup>, Zineb Lesieur<sup>d</sup>, Pierre Tattevin<sup>p</sup>, Bruno Lina<sup>m</sup>, Fabrice Carrat<sup>q,r</sup>, Odile Launay<sup>a,b,c,d</sup> and the FLUVAC Study Group.

- a. Inserm, CIC 1417, Paris, France,
- b. Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- c. Department of Infectious Diseases, CIC Cochin Pasteur, Cochin Broca Hôtel-Dieu hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- d. Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France
- e. CHRU de Montpellier, CIC 1411, Hôpital Saint-Eloi, Montpellier, France
- f. Service d'Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Lyon, France
- g. Emerging Pathogens Laboratory – Fondation Mérieux, Centre International de Recherche en Infectiologie (CIRI) Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, 21, Avenue Tony Garnier, Lyon 69007, France
- h. Inserm CIC 1425, Hôpital Bichat-Claude Bernard, APHP, Paris, France
- i. IAME UMR 1137 ; Univ Paris Diderot, Sorbonne Paris Cité, F-75019, Paris, France
- j. Centre Hospitalo-Universitaire de Rennes, Service de Pneumologie, IRSET UMR 1085, Université de Rennes 1, Rennes, France
- k. CHU Dupuytren, CIC 1435, Limoge Cedex, France
- l. CHU Dupuytren, Service Bactériologie, Virologie, Hygiène, Limoges Cedex, France
- m. CNR Virus Influenza, Hospices Civils de Lyon, Bron, University of Lyon, Lyon, France
- n. CHRU de Montpellier, Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Eloi, Montpellier, France;
- o. Université Lyon 1, Laboratoire de Biométrie et Biologie Evolutive, UMR CNRS 5558
- p. CHRU de Rennes, Service de Maladies Infectieuses et Tropicales, Rennes, France;
- q. Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), F75012, Paris, France
- r. Public health department, Hopital Saint-Antoine, APHP, Paris, France

## Corresponding author :

Pr Odile LAUNAY  
Fédération d'infectiologie  
Groupe Hospitalier Cochin - Saint Vincent de Paul  
27 rue du Faubourg St Jacques  
75679 Paris Cedex 14, France  
Tel: +33 1 58 41 28 58  
Fax: +33 1 58 41 29 10

**Running Title:** Severe influenza-associated hospitalizations in France

**Keywords:** Influenza; Hospitalisation; Adults; Vaccination; Antiviral; Severe

**Length of the abstract:** 249 words

**Length of the paper:** 2 457 words

## Abstract

**Background.** Influenza is an important cause of serious illness and death, particularly in elderly and high-risk groups.

**Objectives.** Aim of this study was to identify factors associated with poor outcomes among adults hospitalized in France for laboratory-confirmed seasonal influenza.

**Study design.** Patients hospitalized for influenza were identified in a prospective, multicenter study carried out in French hospitals during three consecutive influenza seasons (2012-2015). Influenza virus infection was confirmed by reverse transcription polymerase chain reaction. Sociodemographic and clinical variables were compared according to the virus type and subtype. Risk factors for complications, intensive care unit (ICU) admission and death were analyzed by backward stepwise logistic regression.

**Results.** The study population consisted of 566 patients, of whom 56% were older than 65 years and 82% had underlying chronic illnesses. Type A influenza viruses infected 422 patients (75%), including subtype H3N2 in 239 patients (57%). The prior vaccine coverage rate was 38%. Complications occurred in 255 patients (45%), consisting mainly of pneumonia (n=143, 30%) and respiratory failure (n=116, 20%). Eighty-three patients (15%) were admitted to an ICU, and the in-hospital mortality rate was 4% (n=21). Sixty-six patients (12%) received oseltamivir. Age over 65 years was the only identified risk factor for complications. Risk factors for ICU admission were an absence of vaccination, no oseltamivir administration before admission, pre-existing chronic respiratory disease, and current smoking. Age over 65 years and ICU admission were risk factors for death.

**Conclusions.** Older individuals and patients with underlying conditions are most at risk of influenza complications. Vaccination and early oseltamivir administration, both of which are recommended for these patients, appear to reduce ICU admissions.

## **Background**

Influenza is an important cause of serious illness and death, particularly among adults over 65 years old and patients with chronic underlying conditions [1–4]. Each year, 5%–20% of the world population is infected by influenza viruses, and an estimated annual average of 36 000 deaths and 1 200 000 hospital admissions attributable to influenza virus infection occur in the United States [2,5]. Patients over 65 years of age account for 54–70% of hospital admissions and 71–85% of deaths [6].

Influenza is often under-diagnosed in acute-care hospital settings, owing to variable clinical presentations in adults [7–10], late hospital presentation for evaluation or care [11], and predominance of non-pulmonary diagnosis for admissions that may masked the influenza diagnosis [5]. Vaccination is the cornerstone of influenza prevention. Vaccine efficacy is about 60% overall [12] but varies with age, underlying diseases/comorbidities, the predominant viral strain, and the considered outcome. Vaccination reduces the risk of pneumonia [13], hospitalization and death [14–16]. Early antiviral treatment is also recommended for patients at risk of complications [17–19].

## **Objectives**

The aim of this study was to identify factors associated with poor outcomes among adult patients hospitalized for influenza in 6 French university hospitals participating in a multicenter, prospective, hospital-based epidemiological study carried out during three consecutive influenza seasons from 2012 to 2015.

## Study design

We studied cases of laboratory-confirmed influenza occurring during three successive seasons and identified by the FLUVAC study, a French prospective observational hospital-based study [20]. Briefly, we collected data on non-institutionalized adults ( $\geq 18$  years) hospitalized for at least 24 hours in one of the six participating hospitals (Cochin Hospital, Paris; Bichat Hospital, Paris; Rennes Hospital; Limoges Hospital; St. Eloi Hospital, Montpellier; Edouard Herriot Hospital, Lyon) for influenza-like-illness (ILI), with symptom onset less than seven days prior to inclusion, through an active surveillance system composed of healthcare professionals trained to follow the FLUVAC study protocol. ILI was defined as a combination of the following three criteria: (i) sudden symptom onset, (ii) at least one of the following symptoms: fever ( $\geq 38^{\circ}\text{C}$ ), headache, myalgia or malaise, and (iii) at least one of the following respiratory symptoms: cough, sore throat, or shortness of breath (dyspnea) [21]. The “sudden” nature of symptom onset was a subjective concept left to the patients’ appreciation.

Influenza virus infection was detected by applying the reverse transcription-polymerase chain reaction (RT-PCR) to nasopharyngeal swabs (bronchoalveolar lavage fluid or tracheal aspirate for ICU patients). The FLUVAC study (clinicaltrials.gov NCT02027233) respected Good Epidemiological and Clinical Practices in clinical research and the Declaration of Helsinki, and was approved by regional ethics committees.

***Study population and data collection***

We included all laboratory-confirmed (RT-PCR-positive) cases of influenza identified during three consecutive influenza seasons (2012/2013, 2013/2014 and 2014/2015) among the 1452 patients included in the FLUVAC study.

We collected data on demographic characteristics, chronic underlying diseases, hospital admissions in the previous 12 months, smoking status, influenza vaccination in the current season and previous two seasons, the hospitalization ward, and the following characteristics of the current influenza episode: clinical presentation and outcome, including date of onset, hospitalization and treatment; length of hospital stay, treatment, and complications.

Data sources included the hospitals' medical records, interviews with the patients, families and regular physicians; vaccination registries, and laboratory databases. Vaccination status was ascertained during interviews with the patients and their families, and was confirmed from pharmacy records.

***Laboratory data***

The samples were initially tested in the virology laboratories of the participating hospitals by in-house real-time influenza A & B PCR after manual nucleic acid extraction. Amplification was performed in a ABI 7500 thermocycler. All samples were then sent to the French National Influenza Reference Center (CNR-Lyon) for confirmation by RT-PCR. Samples positive in the reference center were molecularly subtyped for viruses known to be circulating at the time namely type A (subtypes H1N1pdm09 and H3N2) and type B. Molecular subtyping was able to determine the H subtype for influenza A and the lineage for influenza B. Subtyping failed in some

cases because of low viral load and samples were thus classified as “unidentifiable”. In case of a discrepancy with local results, the reference center results were considered final. Only the reference center results were taken into account in the analyses.

### ***Statistical analysis***

Results were expressed as means and standard deviation (SD) or medians and interquartile range (IQR) for continuous variables, and N (%) for categorical variables. Age was considered as a binary variable (< and  $\geq$  65 years, the age at which influenza vaccine is recommended in France).

The Wilcoxon rank sum test or Fisher’s exact test was used, as appropriate, for univariable comparisons. To take into account subgroup comparisons, a p value of 0.025 or less was considered statistically significant. Missing data for each variable were excluded from the denominator.

Factors associated with death, complications and ICU admission were identified in a backward stepwise logistic regression model that included all variables with a p value <0.20 in univariate analysis and was adjusted for potential confounders, including “age”, “sex”, “influenza season”, “time from symptom onset to admission” and “chronic respiratory disease”, as appropriate. Results are expressed as odds ratios (OR) and adjusted odds ratios (aOR) with their 95% confidence intervals (95%CI). In the final model, a p value of 0.05 or less was considered statistically significant.

All analyses were performed using Stata software (V12, © Copyright 1996–2014 StataCorpLPt).

## **Results**

### ***Patient characteristics (Table 1)***

A total of 566 cases of laboratory-confirmed influenza were diagnosed during the study period, comprising respectively 162, 112 and 292 cases during the 2012/2013, 2013/2014 and 2014/2015 seasons. Median age was 67 years (IQR, 51-81), 316 patients (56%) were older than 65 years, and 296 patients (52%) were men. Chronic underlying diseases were present in 462 patients (82%), and consisted mainly of chronic respiratory diseases (n= 230, 40% of all patients), chronic heart disease (n=224, 40%) and diabetes (n=140, 25%). Twelve women were pregnant (influenza A/H1N1 in 7 cases, influenza B in 5 cases). Two hundred forty patients (40%) had been hospitalized in the previous year, and the average number of admissions among these 240 patients was 2.2 (SD 2.6). The prior vaccination rate was 38% (215/566). According to French recommendations ([www.sante.gouv.fr/calendrier-vaccinal.html](http://www.sante.gouv.fr/calendrier-vaccinal.html)), 472 patients (88%) should have been vaccinated, but this was the case of only 197 (42%) of these patients. The vaccination rate was 19% (n=47) among patients under 65 years old and 53% (n=168) among patients aged 65 years or more (p=0.001).

**Table 1. Characteristics, clinical presentation and outcomes of the 566 influenza patients diagnosed between 2012 and 2015 in six French University hospitals**

	n	%
<b>Baseline characteristics</b>		
<b>Men</b>	296	52%
<b>Median age, years (IQR)</b>	67 (51-81)	-
<b>Age ≥65 years</b>	316	56%
<b>Median BMI, kg/m<sup>2</sup> (IQR)</b>	25 (22-28)	-
<b>BMI ≥ 40</b>	15	3%
<b>Chronic diseases (indicating Influenza vaccination)</b>	462	82%
Chronic respiratory disease	230	40%
Chronic heart disease	224	40%
Diabetes	140	25%
Chronic renal failure	66	12%
Immunosuppression	56	8%
Others	237	42%



<b>Pregnancy</b>	12	2%*
<b>Current smokers</b>	266	48%
<b>Indication for vaccination</b>	472	88%
<b>Vaccination in current season</b>	215	38%
<b>ICU admission</b>	83	15%
<b>Hospitalization in the previous 12 months</b>	240	42%
<b>Mean number of hospitalizations in the previous 12 months (SD)</b>	2.2 (2.6)	-
<b>among patients hospitalized at least once</b>		
<b><i>Clinical presentation</i></b>		
<b>Median time from symptom onset to hospitalization, days (IQR)</b>	2 (1-3)	
Fever ( $\geq 38^{\circ}\text{C}$ )	504	89%
Cough	487	86%
Dyspnea	387	69%
Sudden symptom onset	289	51%
Weakness/malaise	164	29%
Headache	154	28%
Myalgia	128	23%
<b><i>Outcome and treatment</i></b>		
<b>At least one complication during the hospital stay</b>	255	45%
Pneumonia	143/473	30%
Respiratory failure	116/473	20%
Acute heart failure	67/473	12%
Acute respiratory distress syndrome (ARDS)	58/473	10%
<b>Antiviral use</b>	66	12%
<b>Median length of stay, days (IQR)</b>	6 (3-10)	-
<b>Death</b>	21	4%

IQR: interquartile range

\* Pregnant women represented 2% of all patients and 4% of the 270 women.

### ***Clinical presentation (Table 1)***

Median time from symptom onset to hospitalization was 2 days (IQR, 1-3). The most frequent symptoms were fever and cough, present in respectively 504 (89%) and 487 (86%) cases. Dyspnea was reported by 387 patients (69%). Other symptoms were each present in 20% to 30% of patients. Sudden symptom onset was reported by 289 patients (51%). After adjustment for the influenza season and vaccination status, older age was associated with less intense symptoms. In particular, fever, headache and myalgia were less common in patients over 65 (OR 0.53; 95%CI 0.29-0.96,

p=0.036; OR 0.40; 95%CI 0.26-0.61, p=0.001; and OR 0.39; 95%CI 0.25-0.62, p=0.001, respectively). ICU admission was necessary in 83 cases (15%).

### ***Outcome and treatment (Table 1)***

A total of 473 medical complications related to influenza occurred among 255 patients (45%) during their hospital stay. Pneumonia (143 episodes, 30% of complications), respiratory failure (116, 20%), heart failure (67, 12%) and ARDS (58, 10%) were the most frequent.

Oseltamivir was prescribed to 66 patients (12%), 75% of whom had a chronic underlying condition. Oseltamivir therapy was initiated less than 48 h after symptom onset in 88% of cases.

The median length of hospital stay was 6 days (IQR 3-10).

Twenty-one patients (4%) died during the hospital stay. All of them had at least one chronic underlying disease and 19 (90%) were over 65 years old. The median time from admission to death was 12 days (IQR 7-20).

### ***Virologic data (Table 2)***

Influenza virus type A was detected in 422 patients (75%); it was subtype H1N1 in 163 cases (39%), H3N2 in 239 cases (57%), and “unidentifiable” in 20 cases (4%). Type B was detected in 144 patients (25%), and was subtype Yamagata, Victoria and “unidentifiable” in respectively 115 (80%), 9 (6%) and 20 (14%) cases.

**Table 2. Virologic data for 566 cases of influenza diagnosed between 2012 and 2015 in 6 French University hospitals**

	2012/2013	2013/2014	2014/2015	Total
<b>Influenza cases</b>	<b>162</b>	<b>112</b>	<b>292</b>	<b>566</b>
<b>Type A</b>	80 (49%)	109 (97%)	233 (80%)	422 (75%)
<i>H1N1</i>	30	59	74	163
<i>H3N2</i>	50	44	145	239
Unidentifiable	0	6	14	20
<b>Type B</b>	82 (51%)	3 (3%)	59 (20%)	144 (25%)
<i>Victoria</i>	7	0	2	9
<i>Yamagata</i>	64	3	48	115
Unidentifiable	11	0	9	20
<b>Considered viral circulation</b> <sup>(1)</sup>	A(H1N1)pdm09 + B (Yamagata)	A(H1N1)pdm09 + A(H3N2)	A(H3N2) **	-

(1) From the Flunet database ([http://www.who.int/influenza/gisrs\\_laboratory/flunet/](http://www.who.int/influenza/gisrs_laboratory/flunet/)); Indicate the viral dominant type or subtype;

\*\* circulating strains differed from vaccine strains

Compared to patients with type B influenza, patients with type A influenza were more likely to have a chronic respiratory disease (44% vs 31%,  $p=0.01$ ), dyspnea (72% vs 59%,  $p=0.007$ ) and sudden symptom onset (56% vs 41%,  $p=0.003$ ). (**Table 3**)

Compared to patients with H1N1 influenza, patients with H3N2 influenza were significantly older (73 years, IQR 58-83 vs 60 years, IQR 47-74;  $p=0.001$ ), more likely to have an underlying chronic respiratory disease (45% vs 34%,  $p=0.02$ ) or diabetes (30% vs 18%,  $p=0.01$ ), and more likely to have dyspnea (78% vs 67%,  $p=0.02$ ) and ARDS (15% vs 8%,  $p=0.02$ ). (**Table 3**)

The vaccine coverage rate was higher among patients with H3N2 influenza (45%) than among those with H1N1 influenza (30%,  $p=0.003$ ), in each of the three seasons (**Table 3**).

**Table 3. Characteristics, clinical presentation and outcomes according to virologic data in 566 patients diagnosed with influenza between 2012 and 2015 in 6 French University hospitals**

	A n (%)	B n (%)	p-value	H1N1 n (%)	H3N2 n (%)	p-value
<b>Total</b>	422 (75%)	144 (25%)	-	163 (41%)*	239 (59%)*	-
<b>Baseline characteristics</b>						
<b>Men</b>	222 (53%)	74 (51%)	0.85	88 (54%)	127 (53%)	0.91
<b>Median age, years (IQR)</b>	68 (52-80)	66 (48-88)	0.31	60 (47-74)	73 (58-83)	0.001
<b>Median BMI, kg/m<sup>2</sup> (IQR)</b>	25 (22-28)	24 (21-28)	0.12	26 (22-29)	25 (22-28)	0.86
<b>Chronic diseases (indicating influenza vaccination)</b>	350 (83%)	112 (78%)	0.17	132 (81%)	202 (85%)	0.42
Chronic respiratory disease	185 (44%)	45 (31%)	0.01	55 (34%)	108 (45%)	0.02
Chronic heart disease	173 (41%)	51 (35%)	0.28	67 (41%)	112 (47%)	0.26
Diabetes	107 (25%)	33 (23%)	0.58	30 (18%)	71 (30%)	0.01
Chronic renal failure	47 (11%)	19 (13%)	0.55	13 (8%)	34 (14%)	0.05
Immunosuppression	31 (7%)	15 (10%)	0.29	12 (7%)	19 (8%)	0.98
<b>Pregnancy</b>	7 (2%)	5 (3%)	0.18	7 (4%)	0 (0%)	0.002
<b>Current smoker</b>	209 (50%)	57 (41%)	0.1	91 (56%)	106 (45%)	0.03
<b>Indication for vaccination</b>	356 (91%)	116 (92%)	0.85	138 (92%)	202 (91%)	0.71
<b>Vaccination in current season</b>	161 (39%)	54 (38%)	0.92	49 (30%)	106 (45%)	0.003
<b>ICU admission</b>	66 (16%)	16 (11%)	0.22	29 (18%)	33 (14%)	0.33
<b>Hospitalization in the previous 12 months</b>	238 (56%)	88 (61%)	0.33	97 (60%)	128 (54%)	0.33
<b>Mean number of hospitalizations in the previous 12 months (SD) among patients hospitalized at least once</b>	0.9 (1.6)	1.1 (3.0)	0.19	1 (0.03)	1 (0.02)	0.89
<b>Clinical presentation</b>						
<b>Median time from symptom onset to hospitalization, days (IQR)</b>	2 (1-3)	2 (1-4)	0.12	2 (1-3)	2 (1-3)	0.30
Fever ( $\geq 38^{\circ}\text{C}$ )	378 (90%)	126 (88%)	0.54	151 (92%)	207 (87%)	0.08
Cough	365 (87%)	122 (85%)	0.58	143 (88%)	205 (86%)	0.66
Dyspnea	302 (72%)	85 (59%)	0.001	127 (78%)	161 (67%)	0.02

Sudden symptom onset	236 (56%)	59 (41%)	0.03	85 (53%)	143 (61%)	0.3
Weakness/malaise	118 (28%)	46 (32%)	0.39	44 (27%)	70 (29%)	0.65
Headache	109 (26%)	45 (31%)	0.23	51 (31%)	46 (19%)	0.07
Myalgia	94 (22%)	34 (24%)	0.71	43 (27%)	46 (19%)	0.09
<b>Outcome and treatment</b>						
<b>At least one complication during the hospital stay</b>						
Pneumonia	198 (47%)	48 (39%)	0.09	76 (47%)	113 (47%)	0.92
Respiratory failure	100 (24%)	43 (30%)	0.15	38 (23%)	55 (23%)	1.0
Acute heart failure	91 (22%)	25 (17%)	0.34	35 (21%)	51 (21%)	1.0
ARDS	54 (13%)	13 (9%)	0.30	21 (13%)	30 (12%)	0.96
Antiviral use	46 (11%)	12 (8%)	0.43	25 (15%)	19 (8%)	0.02
Median length of stay, days (IQR)	51 (12%)	15 (11%)	0.73	24 (15%)	26 (11%)	0.28
Death	6 (3-10)	5 (2-9)	0.025	7 (3-10)	6 (3-10)	0.59
	15 (3%)	6 (4%)	0.79	4 (2%)	10 (4%)	0.42

IQR: interquartile range; SD: standard deviation

\* Twenty patients with an “unidentifiable” subtype of type A influenza were excluded from the comparison

### ***Factors influencing outcome***

The median hospital stay was longer among patients with influenza A than those with influenza B (5 days, IQR 2-9 vs 6 days, IQR 3-10;  $p=0.02$ ) but was similar across A subtypes (**Table 3**). Vaccination status did not influence the length of stay. The patients who died had type A/H3N2 ( $n=10$ ), A/H1N1 ( $n=4$ ), A/unidentifiable ( $n=1$ ), or B ( $n=6$ ) influenza. The mortality rate did not differ according to the virus type or subtype, vaccination status, or the influenza season. The virus types and subtypes did not influence these outcomes, and neither did the time from symptom onset to hospitalization.

### ***Multivariate analysis***

After adjustment for age, sex, the influenza season and time from symptom onset to admission, the risk of ICU admission was increased by the absence of antiviral therapy, no prior influenza vaccination, current smoking, and chronic respiratory disease (all  $p<0.05$ ) (**Table 4**).

**Table 4. Risk factors for ICU admission among 566 patients hospitalized for influenza from 2012 to 2015, as identified in the final logistic regression model**

	aOR (95%CI)	p value
<b>Age <math>\geq 65</math> years</b>	0.77 (0.45-1.30)	0.33
<b>Female gender</b>	0.79 (0.47-1.32)	0.36
<b>Influenza season</b>		
<b>2012/2013</b>	1 (Ref.)	-
<b>2013/2014</b>	1.12 (0.50-2.48)	0.78
<b>2014/2015</b>	1.73 (0.92-3.24)	0.09
<b>Time between symptom onset and admission*</b>	1.1 (0.89-1.15)	0.88
<b>Vaccination in current season</b>	0.50 (0.28-0.90)	0.02
<b>Oseltamivir use</b>	0.35 (0.19-0.66)	0.01
<b>Current smoking</b>	1.82 (1.06-3.12)	0.04
<b>Chronic respiratory disease</b>	1.66 (1.01-2.77)	0.05

*The outcome analyzed was ICU admission during the initial hospital stay.*

*The model was adjusted for “sex”, “age”, “influenza season” and “time from symptom onset to admission”.*

*\*Continuous variable*

aOR: adjusted odds ratio; 95%CI: 95% confidence interval; Ref.: Reference

After adjustment for sex, the influenza season, time from symptom onset to admission, and chronic respiratory disease, the only risk factor for clinical complications was age over 65 years (OR 1.72; 95%CI 1.22-2.44,  $p=0.002$ ). After the same adjustment, age over 65 years (OR 10.31; 95%CI 2.31-45.90,  $p=0.002$ ) and ICU admission (OR 5.37; 95%CI 2.0-14.56,  $p=0.001$ ) were both associated with the risk of death.

## Discussion

This prospective multicenter study involved 566 patients with laboratory-confirmed influenza admitted to 6 hospitals during three winter seasons, from 2012 to 2015. Most of the patients were over 65 years old and had at least one underlying disease. Nearly half the patients developed influenza complications during their hospital stay. Antiviral therapy and vaccination had a preventive effect on ICU admission.

Older age and chronic underlying conditions are known risk factors for severe influenza. In a Spanish multicenter study comparing influenza inpatients and outpatients in 2010/2011, Castilla *et al.* found that hospitalized patients were older and had more chronic diseases [22].

We found that patients over 65 years old tended to have atypical symptoms, confirming previous reports [23]. Babcock *et al.* and Walsh *et al.*, studying respectively 207 and 56 elderly patients hospitalized with influenza, found that cough and fever were the most common symptoms, while fever was absent in around 30% of cases [10,24]. We found a high rate of complications, ICU admission and death, confirming the severity of influenza in older patients with underlying conditions [11,25].

Vaccination rates varied according to the influenza virus type and subtype, underlining differences in vaccine efficacy between these groups, owing mainly to differences in age and underlying conditions. In particular, the vaccination rate was higher among patients with H3N2 infection, suggesting that vaccination was less effective in this subgroup. This may be due partly to immune senescence, as these patients were significantly older than patients with H1N1 infection, and partly to vaccine mismatch in the northern hemisphere during the 2014-2015 season, due to A/H3N2 antigenic drift from the vaccine virus, while subtype A/H3N2 accounted for more than 70% of all subtyped influenza A viruses [26].

Vaccination of elderly persons prevents only 30-40% of influenza cases, and its impact on the severity of influenza is controversial [27,28]. However, many studies have shown a beneficial impact of vaccination on hospitalization, complications and death [22,29–34]. More recently, Grijalva *et al.* reported that vaccination reduced hospitalizations for influenza-associated pneumonia by 56% in a large US case-control study [13].

We found no impact of vaccination on mortality, whereas ICU admission was less frequent among vaccinees, underlining the importance of vaccination for at-risk patients.

In a recent study of 5614 patients hospitalized for laboratory-confirmed influenza, selected from a US population-based influenza-related hospitalization surveillance system during the 2012/2013 season, Arriola *et al.* found that 71% of patients were over 65 years old, 91% had medical conditions, 14% were admitted to an ICU, and 2% died. Fifty-five percent of the patients had been vaccinated. No association was found between vaccination status and ICU admission, death, pneumonia, or the length of hospital or ICU stay. However, after restricting the analysis to patients treated with



antiviral drugs and matching them for a vaccination propensity score, they found that the length of ICU stay was reduced by a factor of 0.6 (95%CI 0.4-0.8) among vaccinated 50- to 64-year-olds compared to their unvaccinated counterparts. A similar but non significant trend was found among patients aged from 65 to 74 [25]. Castilla *et al.* found that vaccination protected against severe influenza, defined as ICU admission or in-hospital death, and suggested that vaccination might be more effective in preventing severe than mild illness [22]. By comparison with the latter study, antiviral use in our patients was very low, probably owing to a lack of diagnostic confirmation during the recommended period of antiviral introduction (<48h after symptom onset). We found that antiviral use was associated with a lower risk of ICU admission among patients with underlying respiratory diseases, but not with lower mortality. These results are in agreement with several studies showing a reduction in mortality and complications among patients with severe influenza who received antivirals [19,35–38].

The strengths of this study include the large number of patients hospitalized for influenza, the multicenter, prospective design, uniform patient screening in the different centers, diagnostic confirmation in an influenza reference center, the lengthy study period spanning three consecutive influenza seasons, and precise documentation of influenza virus types and subtypes. Several limitations must also be acknowledged. First, as all the participating centers were teaching hospitals, the proportion of patients with underlying diseases may have been higher than in the general population, owing to a referral bias. Second, although the sample was large, the study was probably underpowered to identify a moderate impact of antivirals and vaccination on mortality. Finally, a small number of samples were misclassified by on-site tests, 9 false positives and 25 false negatives being identified by centralized

testing in the reference center. This should be taken into account when considering the way patients were treated.

In conclusion, most patients hospitalized for severe influenza in France are elderly individuals with underlying conditions, leading to a high risk of complications and ICU admission. It is noteworthy that almost all the patients in this study qualified for influenza vaccination according to national guidelines. As recommended, antiviral treatment should be used in the first 48h after 'flu-like symptom onset in order to reduce the duration of required medical care.

## **Acknowledgments**

The study sites received funding from Sanofi Pasteur and Sanofi Pasteur MSD for the FLUVAC study. Vaccine producers had no role in the study design, data analysis, decision to publish or preparation of the manuscript. From SPMSD, the authors thank H el ene Bricout, Laurence Pagnon and Christine Sadorge for their inputs during the study design phase and for critical review of the results.

We are very grateful to the following persons and institutions who made significant contributions to the FLUVAC study:

**R eseau National d'Investigation Clinique en Vaccinologie (I-REIVAC):** K. Seddik, Z. Lesieur, N. Lenzi; **InVS, France:** I. Bonmarin; **FLUVAC Study group:** **H opital Cochin, Paris:** O. Launay, P. Loulergue, H. Bodilis, M. Servera-Miyalou, I. Sadler, S. Momcilovic, R. Kanaan, N. Coolent, K. Tan Boun, P. Blanche, J. Charpentier, F. Daviaud, N. Mongardon, A. Bretagnol, Y.E. Claessens, F. Rozenberg, A. Krivine. **H opital Bichat Claude-Bernard, Paris:** Y. Yazdanpanah, C. Burdet, S. Harent, M. Lachatre, C. Rioux, A. Bleibtreu, E. Casalino, C. Choquet, A. Leleu, K. Belghalem, L. Colosi, M. Ranaivoson, V. Verry, L. Pereira, E. Dupeyrat, J. Bernard, N.

Emeyrat, P. Chavance, A. Debit, M. Aubier, P. Pradere, A. Justet, H. Mal, O. Brugiere, T. Papo, T. Goulenok, M. Boisseau, R. Jouenne, JF. Alexandra, A. Raynaud-Simon, M. Lilamand, A. Cloppet-Fontaine, K. Becheur, AL. Pelletier, N. Fidouh, P. Ralaimazava, F. Beaumale, Y. Costa, X. Duval. **Hôpital Edouard Herriot, Lyon:** E. Munier, F. Betend, S. Amour, S. Loeffert, K. Francourt. **Hôpital Saint-Eloi, Montpellier:** C. Merle, F. Galtier, F. Letois, V. Foulongne, P. Géraud, V. Driss, S. Noslier, M. Ray, M. Sebbane, A. Konaté, A. Bourdin, K Klouche, M.S. Léglise. **CHU Dupuytren, Limoges:** D. Postil, E. Couve-Deacon, D. Fruit, C. Fenerol, C. Vallejo, S. Alain, S. Rogez; **CHU Pontchaillou, Rennes:** P. Tattevin, S. Jouneau, F. Lainé, E. Thébault, G. Lagathu, P. Fillatre, C. Le Pape, L. Beuzit; **Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136):** F. Carrat, F. Chau, I. Goderel

## References

1. WHO | Influenza (Seasonal) [Internet]. WHO [cité 2015 août 5]; Available from: <http://www.who.int.gate2.inist.fr/mediacentre/factsheets/fs211/en/>
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the united states. *JAMA* 2004;292:1333-40.
3. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng P-Y, Steiner C, et al. Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008. *Clin. Infect. Dis.* 2012;54:1427-36.
4. Hak E, Wei F, Nordin J, Mullooly J, Poblete S, Nichol KL. Development and Validation of a Clinical Prediction Rule for Hospitalization Due to Pneumonia or Influenza or Death during Influenza Epidemics among Community-Dwelling Elderly Persons. *J. Infect. Dis.* 2004;189:450-8.
5. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. *Clin. Infect. Dis.* 2009;48:1003-32.
6. Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, et al. Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States. *PLoS ONE* 2015;10:e0118369.
7. Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney W. Does this patient have influenza? *JAMA* 2005;293:987-97.
8. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults

hospitalized with influenza. *Arch. Intern. Med.* 2007;167:354-60.

9. Babcock HM, Merz LR, Dubberke ER, Fraser VJ. Case-control study of clinical features of influenza in hospitalized patients. *Infect. Control Hosp. Epidemiol.* 2008;29:921-6.
10. Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. *J. Am. Geriatr. Soc.* 2002;50:1498-503.
11. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. *Antivir. Ther.* 2012;17:143-57.
12. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect. Dis.* 2012;12:36-44.
13. Grijalva CG, Zhu Y, Williams DJ, et al. Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. *JAMA* 2015;1488-97.
14. Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, Griffin MR. Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Adults, 2011–2012 Influenza Season. *Clin. Infect. Dis.* 2013;56:1774-7.
15. Bonmarin I, Belchior E, Lévy-Bruhl D. Impact of influenza vaccination on mortality in the French elderly population during the 2000–2009 period. *Vaccine* 2015;33:1099-101.
16. Estimated Influenza Illnesses and Hospitalizations Averted by Influenza Vaccination — United States, 2012–13 Influenza Season [Internet]. [cité 2015 août 4]; Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6249a2.htm>
17. Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, et al. Treatment with

neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* 2012;55:1198-204.

18. Lee N, Cockram CS, Chan PKS, Hui DSC, Choi KW, Sung JJY. Antiviral Treatment for Patients Hospitalized with Severe Influenza Infection May Affect Clinical Outcomes. *Clin. Infect. Dis.* 2008;46:1323-4.

19. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, Canada. *Clin. Infect. Dis.* 2007;45:1568-75.

20. Rondy M, Puig-Barbera J, Launay O, Duval X, Castilla J, Guevara M, et al. 2011–12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study. *PLoS ONE* 2013;8:e59681.

21. Influenza case definitions [Internet]. [cité 2015 juin 17]; Available from: [http://ecdc.europa.eu/en/activities/surveillance/eisn/surveillance/pages/influenza\\_case\\_definitions.aspx](http://ecdc.europa.eu/en/activities/surveillance/eisn/surveillance/pages/influenza_case_definitions.aspx)

22. Castilla J, Godoy P, Domínguez Á, Martínez-Baz I, Astray J, Martín V, et al. Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed Influenza. *Clin. Infect. Dis.* 2013;57:167-75.

23. Monmany J, Rabella N, Margall N, Domingo P, Gich I, Vázquez G. Unmasking Influenza Virus Infection in Patients Attended to in the Emergency Department. *Infection* 2004;32:89-97.

24. Babcock HM, Merz LR, Fraser VJ. Is influenza an influenza-like illness? *Clinical*

presentation of influenza in hospitalized patients. *Infect. Control Hosp. Epidemiol.*

2006;27:266-70.

25. Arriola CS, Anderson EJ, Baumbach J, Bennett N, Bohm S, Hill M, et al. Does influenza vaccination modify influenza disease severity? Data on older adults hospitalized with influenza during the 2012-13 season in the United States. *J. Infect. Dis.* 2015;

26. Puig-Barberà J, Martínez C, Cano L, Díez J, López-Labrador FX. Influenza H3N2 antigenic drift in hospital admissions with influenza during the 2014–2015 season in the Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease, Valencia (Spain). *J. Clin. Virol.* 2015;70:S63.

27. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst. Rev.* 2010;CD001269.

28. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. *Lancet Infect. Dis.* 2007;7:658-66.

29. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The Efficacy of Influenza Vaccine in Elderly Persons A Meta-Analysis and Review of the Literature. *Ann. Intern. Med.* 1995;123:518-27.

30. Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. *Vaccine* 2010;28:7267-72.

31. McLean HQ, Meece JK, Belongia EA. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness. *Vaccine* 2014;32:453-7.

32. Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. *Am. J. Epidemiol.* 2009;170:650-6.
33. Darvishian M, Gefenaite G, Turner RM, Pechlivanoglou P, Van der Hoek W, Van den Heuvel ER, et al. After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly. *J. Clin. Epidemiol.* 2014;67:734-44.
34. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. *Lancet Infect. Dis.* 2014;14:1228-39.
35. Lee N, Choi KW, Chan PKS, Hui DSC, Lui GCY, Wong BCK, et al. Outcomes of adults hospitalised with severe influenza. *Thorax* 2010;65:510-5.
36. Moscona A. Neuraminidase Inhibitors for Influenza. *N. Engl. J. Med.* 2005;353:1363-73.
37. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. IMpact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. *Arch. Intern. Med.* 2003;163:1667-72.
38. Hiba V, Chowders M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. *J. Antimicrob. Chemother.* 2011;66:1150-5.